Abstract

Picornaviridae represent a large family of single-stranded positive RNA viruses of which different members can infect both humans and animals. These include the enteroviruses (e.g., poliovirus, coxsackievirus, and rhinoviruses) as well as the cardioviruses (e.g., encephalomyocarditis virus). Picornaviruses have evolved to interact with, use, and/or evade cellular host systems to create the optimal environment for replication and spreading. It is known that viruses modify kinase activity during infection, but a proteome-wide overview of the (de)regulation of cellular kinases during picornavirus infection is lacking. To study the kinase activity landscape during picornavirus infection, we here applied dedicated targeted mass spectrometry-based assays covering ~40% of the human kinome. Our data show that upon infection, kinases of the MAPK pathways become activated (e.g., ERK1/2, RSK1/2, JNK1/2/3, and p38), while kinases involved in regulating the cell cycle (e.g., CDK1/2, GWL, and DYRK3) become inactivated. Additionally, we observed the activation of CHK2, an important kinase involved in the DNA damage response. Using pharmacological kinase inhibitors, we demonstrate that several of these activated kinases are essential for the replication of encephalomyocarditis virus. Altogether, the data provide a quantitative understanding of the regulation of kinome activity induced by picornavirus infection, providing a resource important for developing novel antiviral therapeutic interventions.

Original languageEnglish
Article number100757
JournalMolecular and Cellular Proteomics
Volume23
Issue number5
Early online date29 Mar 2024
DOIs
Publication statusPublished - May 2024

Bibliographical note

Publisher Copyright:
© 2024 American Society for Biochemistry and Molecular Biology Inc.. All rights reserved.

Funding

Acknowledgments\u2014This work has been supported by the NWO funded Netherlands Proteomics Centre through the National Road Map for Large-scale Infrastructures program X-Omics, Project 184.034.019, and by CARE, a project that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 101005077.

FundersFunder number
Nederlandse Organisatie voor Wetenschappelijk Onderzoek
Andy Hill CARE Fund
Netherlands Proteomics Centre184.034.019
Innovative Medicines Initiative101005077
Innovative Medicines Initiative

    Fingerprint

    Dive into the research topics of 'Assessment of Kinome-wide Activity Remodeling Upon Picornavirus Infection'. Together they form a unique fingerprint.

    Cite this